Brian I Rini

List of Publications by Year
in descending order

400 papers	50,885 citations	2802 94 h-index	1676 214 g-index
409 all docs	409 docs citations	409 times ranked	32768 citing authors

#	Article	IF	Citations
1	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European Urology Oncology, 2022, 5, 225-234.	5.4	17
2	A Modern Assessment of Cancer Risk in Adrenal Incidentalomas. Annals of Surgery, 2022, 275, e238-e244.	4.2	34
3	Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 64.e17-64.e24.	1.6	3
4	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. European Urology, 2022, 81, 266-271.	1.9	33
5	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research, 2022, 28, 738-747.	7.0	11
6	Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2022, 40, TPS404-TPS404.	1.6	0
7	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 275.	7.1	75
8	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. Journal of Clinical Oncology, 2022, 40, 352-352.	1.6	8
9	Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Current Oncology Reports, 2022, 24, 695-702.	4.0	9
10	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitorâ€“Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. Journal of Clinical Oncology, 2022, 40, 1929-1938.	1.6	33
11	Conditional survival and longâ€term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 2022, 128, 2085-2097.	4.1	103
12	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	7.0	12
13	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNÎ± Â± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical Cancer Research, 2022, 28, 2771-2778.	7.0	8
14	Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC).. Journal of Clinical Oncology, 2022, 40, 3002-3002.	1.6	6
15	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. European Urology, 2021, 79, 659-662.	1.9	64
16	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. Clinical Genitourinary Cancer, 2021, 19, e12-e16.	1.9	6
17	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clinical Infectious Diseases, 2021, 72, e835-e843.	5.8	103
18	Summary from the Kidney Cancer Associationâ€™s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 2021, 19, 167-175.	1.9	4

#	Article	IF	Citations
19	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	7.0	154
20	Severity of illness scores at presentation predict ICU admission and mortality in COVID-19. Journal of Emergency and Critical Care Medicine, 2021, 5, 7-7.	0.7	19
21	Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2021, 39, 341-341.	1.6	0
22	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European Urology, 2021, 79, 334-338.	1.9	39
23	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers, 2021, 13, 1475.	3.7	10
24	Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. Cancer Causes and Control, 2021, 32, 675-680.	1.8	6
25	Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors?. Lancet Oncology, The, 2021, 22, 593-594.	10.7	1
26	Perspectives on under-representation of minority patients (pts) in clinical trials.. Journal of Clinical Oncology, 2021, 39, e18521-e18521.	1.6	0
27	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell, 2021, 184, 2988-3005.e16.	28.9	166
28	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. European Urology, 2021, 79, 665-673.	1.9	20
29	Care without a compass: Including patients with cancer in COVID-19 studies. Cancer Cell, 2021, 39, 895-896.	16.8	14
30	The CoVIDâ€TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	3.8	23
31	A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Targeted Oncology, 2021, 16, 633-642.	3.6	8
32	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 155, 291-293.	2.8	19
33	COVID-19 and Cancer. JAMA Oncology, 2021, 7, 1882.	7.1	42
34	PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation. Cell Reports, 2021, 36, 109747.	6.4	9
35	Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. , 2021, 9, e003281.		9
36	Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clinical Genitourinary Cancer, 2021, 19, 468.e1-468.e5.	1.9	7

#	Article	IF	Citations
37	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, 19, e306-e312.	1.9	12
38	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research, 2021, 9, 80.	6.8	16
39	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research, 2021, 27, 6687-6695.	7.0	25
40	906â€…Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme. , 2021, 9, A951-A951.		0
41	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 2021, 4, e2134330.	5.9	32
42	Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 662723.	2.8	11
43	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. European Urology, 2021, , .	1.9	9
44	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. Journal of Oncology Pharmacy Practice, 2020, 26, 891-905.	0.9	0
45	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 793-803.	7.0	117
46	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. European Urology, 2020, 77, 449-453.	1.9	52
47	Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 429-435.	1.9	45
48	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discovery, 2020, 10, 40-53.	9.4	219
49	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncology, The, 2020, 21, 95-104.	10.7	160
50	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1563-1573.	10.7	466
51	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
52	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. Targeted Oncology, 2020, 15, 477-483.	3.6	4
53	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	4.5	343
54	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery, 2020, 10, 1514-1527.	9.4	108

#	Article	IF	Citations
55	The immunology of renal cell carcinoma. Nature Reviews Nephrology, 2020, 16, 721-735.	9.6	229
56	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open, 2020, 5, e000852.	4.5	18
57	To Treat or Not to Treatâ€"Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic. JAMA Oncology, 2020, 6, 1868.	7.1	6
58	Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers, 2020, 12, 2662.	3.7	31
59	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. European Urology, 2020, 78, 783-785.	1.9	20
60	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British Journal of Cancer, 2020, 123, 1590-1598.	6.4	57
61	Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports. Frontiers in Oncology, 2020, 10, 609235.	2.8	9
62	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	16.8	26
63	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell, 2020, 38, 803-817.e4.	16.8	262
64	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. Future Oncology, 2020, 16, 1199-1210.	2.4	4
65	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	13.7	1,395
66	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
67	MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma. Molecular Metabolism, 2020, 34, 136-145.	6.5	18
68	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. Targeted Oncology, 2020, 15, 211-220.	3.6	14
69	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. British Journal of Cancer, 2020, 123, 898-904.	6.4	36
70	Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. BMC Urology, 2020, 20, 84.	1.4	12
71	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology, 2020, 6, 293-306.	1.8	4
72	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treatment Reviews, 2020, 84, 101966.	7.7	44

#	Article	IF	Citations
73	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. Clinical Genitourinary Cancer, 2020, 18, 500-508.	1.9	10
74	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. Cancer Cell, 2020, 37, 738-741.	16.8	46
75	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology, 2020, 78, 615-623.	1.9	44
76	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-NaÃ¯ve Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2506-2514.	7.0	20
77	Patientâ€reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU International, 2020, 126, 73-82.	2.5	19
78	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. Clinical Cancer Research, 2020, 26, 2087-2095.	7.0	35
79	COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell, 2020, 38, 629-646.	16.8	196
80	Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight, 2020, 5, .	5.0	55
81	Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101.. Journal of Clinical Oncology, 2020, 38, 5061-5061.	1.6	6
82	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, 5062-5062.	1.6	3
83	Phase III study of the hypoxia-inducible factor 2Î± (HIF-2Î±) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2020, 38, TPS5094-TPS5094.	1.6	8
84	Gender impact on renal cell carcinoma survival: A population-based analysis.. Journal of Clinical Oncology, 2020, 38, e17099-e17099.	1.6	0
85	Data to decisions: The impact of online education on immunotherapy in advanced renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, e17076-e17076.	1.6	0
86	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	10.7	594
87	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2019, 20, 1386-1394.	10.7	69
88	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2019, 2, 505-514.	5.4	50
89	HIF Inhibitors: Status of Current Clinical Development. Current Oncology Reports, 2019, 21, 6.	4.0	230
90	Adjuvant therapy in renal cell carcinoma. Cancer, 2019, 125, 2935-2944.	4.1	47

#	Article	IF	Citations
91	Immunotherapy for renal cell carcinoma. Expert Opinion on Biological Therapy, 2019, 19, 897-905.	3.1	14
92	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	13.7	778
93	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. , 2019, 7, 127.		23
94	A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer, 2019, 125, 2400-2408.	4.1	18
95	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115.	27.0	1,824
96	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1116-1127.	27.0	2,319
97	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 2019, 17, 177-182.	1.9	11
98	Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs. Cancer Immunology Research, 2019, 7, 1687-1699.	3.4	33
99	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
100	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer, 2019, 17, 65-71.	1.9	9
101	Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma. JAMA Oncology, 2019, 5, 411.	7.1	63
102	Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. BMC Cancer, 2019, 19, 17.	2.6	4
103	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 297-310.	10.7	207
104	Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens. American Journal of Clinical Pathology, 2019, 151, 217-225.	0.7	25
105	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. Oncologist, 2019, 24, 4-8.	3.7	7
106	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research, 2019, 25, 210-221.	7.0	48
107	Radical shifts in the first-line management of metastatic renal cell carcinoma. Nature Reviews Clinical Oncology, 2019, 16, 71-72.	27.6	4
108	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. Clinical Genitourinary Cancer, 2019, 17, e505-e512.	1.9	24

#	Article	IF	Citations
109	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. Journal of Clinical Oncology, 2019, 37, 4500-4500.	1.6	85
110	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. Journal of Clinical Oncology, 2019, 37, 4513-4513.	1.6	61
111	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncology, The, 2018, 19, 451-460.	10.7	228
112	Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes. Clinical Cancer Research, 2018, 24, 2979-2980.	7.0	6
113	A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	7.0	7
114	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Targeted Oncology, 2018, 13, 353-361.	3.6	14
115	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 405-412.	1.6	40
116	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clinical Genitourinary Cancer, 2018, 16, e879-e892.	1.9	25
117	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. Clinical Genitourinary Cancer, 2018, 16, e663-e667.	1.9	12
118	Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 2018, 14, 861-875.	2.4	15
119	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clinical Genitourinary Cancer, 2018, 16, 298-304.	1.9	41
120	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e751-e760.	1.9	17
121	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	27.0	3,334
122	Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis. Clinical Genitourinary Cancer, 2018, 16, e289-e295.	1.9	10
123	Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map Analysis. Urology Practice, 2018, 5, 383-390.	0.5	3
124	Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation. Urology, 2018, 113, e1-e2.	1.0	1
125	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e437-e442.	1.9	23
126	Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy. Clinical Genitourinary Cancer, 2018, 16, e1077-e1082.	1.9	11

#	Article	IF	Citations
127	Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 31-37.	1.6	49
128	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2Î± Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 867-874.	1.6	290
129	Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer. Journal of Clinical Oncology, 2018, 36, 3639-3644.	1.6	9
130	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. Targeted Oncology, 2018, 13, 599-609.	3.6	22
131	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2018, 124, 3677-3683.	4.1	53
132	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
133	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. Clinical Genitourinary Cancer, 2018, 16, e1237-e1242.	1.9	34
134	Information Transparency in the Drug Approval Process. JAMA Oncology, 2018, 4, 1621.	7.1	1
135	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. British Journal of Cancer, 2018, 119, 160-163.	6.4	39
136	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. Clinical Cancer Research, 2018, 24, 4407-4415.	7.0	50
137	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
138	Important Group Differences on the Functional Assessment of Cancer Therapyâ€“Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. Value in Health, 2018, 21, 1413-1418.	0.3	7
139	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.	0.4	10
140	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 413-419.e1.	1.9	21
141	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	30.7	900
142	Treatment selection for men with metastatic prostate cancer who progress on upfront chemoâ€hormonal therapy. Prostate, 2018, 78, 1035-1041.	2.3	11
143	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 3333-3340.	8.2	43
144	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 4511-4511.	1.6	12

#	Article	IF	Citations
145	Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more. Oncotarget, 2018, 9, 14036-14037.	1.8	1
146	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.	1.9	65
147	A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 1764-1769.	1.6	36
148	Specific immunotherapy in renal cancer: a systematic review. Therapeutic Advances in Urology, 2017, 9, 45-58.	2.0	5
149	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal CellÂCarcinoma. Clinical Genitourinary Cancer, 2017, 15, 403-410.e2.	1.9	14
150	Overall survival of firstâ€line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. Cancer Science, 2017, 108, 1231-1239.	3.9	21
151	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Targeted Oncology, 2017, 12, 333-340.	3.6	5
152	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3557-3565.	7.0	19
153	On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. Expert Review of Anticancer Therapy, 2017, 17, 97-99.	2.4	3
154	Future Challenges for Drug Development in Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 577-579.	1.6	6
155	Treatment of renal cell carcinoma: Current status and future directions. Ca-A Cancer Journal for Clinicians, 2017, 67, 507-524.	329.8	583
156	Emerging immunotherapy in advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 687-693.	1.6	14
157	Imaging strategy and outcome following partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 660.e1-660.e8.	1.6	8
158	HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nature Communications, 2017, 8, 1769.	12.8	303
159	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology, 2017, 71, 970-978.	1.9	12
160	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1Î², IL8, CXCL5, and Mip-1Î±. Clinical Cancer Research, 2017, 23, 2346-2355.	7.0	148
161	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e275-e280.	1.9	19
162	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer, 2017, 1, 41-47.	0.4	13

#	Article	IF	Citations
163	Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer, 2017, 3, 57-63.	0.4	39
164	Management of the small renal mass. Translational Andrology and Urology, 2017, 6, 923-930.	1.4	32
165	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 2017, 35, 3851-3858.	1.6	384
166	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3916-3923.	1.6	316
167	Comparative Effectiveness of Tumor Response Assessment Methods: Standard of Care Versus Computer-Assisted Response Evaluation. JCO Clinical Cancer Informatics, 2017, 1, 1-16.	2.1	3
168	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget, 2017, 8, 1204-1212.	1.8	6
169	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 113-117.	3.8	11
170	Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 1224-1231.	3.7	54
171	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 499-503.	1.9	39
172	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. JAMA Oncology, 2016, 2, 1179.	7.1	154
173	Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. International Urology and Nephrology, 2016, 48, 1253-1260.	1.4	12
174	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2016, 16, 577-584.	2.4	12
175	Emerging therapeutics in refractory renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2016, 17, 1225-1232.	1.8	15
176	Changing Landscape of Refractory Renal Cell Carcinoma. Journal of Oncology Practice, 2016, 12, 422-423.	2.5	0
177	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Journal of Clinical Oncology, 2016, 34, 3655-3663.	1.6	174
178	Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?. Clinical Cancer Research, 2016, 22, 5626-5628.	7.0	6
179	Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Japanese Journal of Clinical Oncology, 2016, 46, 1031-1041.	1.3	20
180	Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunology Research, 2016, 4, 948-958.	3.4	26

#	Article	IF	Citations
181	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1599-1611.	10.7	181
182	Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncology, The, 2016, 17, 1317-1324.	10.7	200
183	MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. British Journal of Cancer, 2016, 115, 920-928.	6.4	43
184	Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. Journal of Neurosurgery: Spine, 2016, 25, 766-774.	1.7	51
185	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. Clinical Pharmacokinetics, 2016, 55, 1251-1269.	3.5	29
186	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 917-927.	10.7	789
187	Axitinib for the treatment of metastatic renal cell carcinoma. Future Oncology, 2016, 12, 303-311.	2.4	6
188	Prospective Clinical Study of Precision Oncology in Solid Tumors. Journal of the National Cancer Institute, 2016, 108, .	6.3	70
189	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	7.0	193
190	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 2016, 70, 358-364.	1.9	133
191	Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 1660-1668.	1.6	99
192	Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted Oncology, 2016, 11, 229-234.	3.6	17
193	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. European Urology, 2016, 69, 345-351.	1.9	53
194	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 113-117.	3.8	7
195	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine, 2015, 2, 1814-1820.	6.1	13
196	Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.3	2
197	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. Journal of Urology, 2015, 194, 297-303.	0.4	80
198	Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma. JAMA Oncology, 2015, 1, 212.	7.1	9

#	Article	IF	Citations
199	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncology, The, 2015, 16, 676-685.	10.7	229
200	Relapse models for clear cell renal carcinoma â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e378.	10.7	0
201	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2015, 13, e79-e85.	1.9	78
202	Toward individualized treatment in urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 170.	1.6	0
203	Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 112.e15-112.e21.	1.6	60
204	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncology, The, 2015, 16, 293-300.	10.7	299
205	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 621-629.	1.9	75
206	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823.	27.0	1,004
207	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. British Journal of Cancer, 2015, 113, 1571-1580.	6.4	88
208	Algorithms in the Firstâ€Line Treatment of Metastatic Clear Cell Renal Cell Carcinomaâ€”Analysis Using Diagnostic Nodes. Oncologist, 2015, 20, 1028-1035.	3.7	23
209	Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 540-547.e7.	1.9	22
210	Emerging therapeutic approaches in renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 1305-1314.	2.4	16
211	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European Urology, 2015, 68, 506-515.	1.9	41
212	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer, 2015, 13, 150-155.	1.9	10
213	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. European Journal of Clinical Pharmacology, 2015, 71, 1477-1484.	1.9	19
214	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology, 2015, 33, 1430-1437.	1.6	914
215	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. European Urology, 2015, 67, 85-97.	1.9	403
216	Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma. Clinical Pharmacokinetics, 2015, 54, 397-407.	3.5	12

#	Article	IF	Citations
217	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Targeted Oncology, 2015, 10, 45-53.	3.6	45
218	The use of sunitinib in renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy, 2014, 14, 983-999.	2.4	7
219	Progressionâ€free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer, 2014, 120, 52-60.	4.1	40
220	Surgical Outcomes After Cytoreductive Nephrectomy With Inferior Vena Cava Thrombectomy. Urology, 2014, 84, 1414-1419.	1.0	30
221	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clinical Genitourinary Cancer, 2014, 12, 354-358.	1.9	26
222	The ineligible patient: how to treat patients not included in clinical studies. World Journal of Urology, 2014, 32, 9-18.	2.2	9
223	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. European Urology, 2014, 65, 577-584.	1.9	207
224	Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial. Journal of Clinical Oncology, 2014, 32, 752-759.	1.6	179
225	Molecular Biomarkers in Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2014, 20, 2060-2071.	7.0	62
226	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2014, 66, 704-710.	1.9	382
227	Dual VEGF/VEGFR inhibition in advanced solid malignancies. Cancer Biology and Therapy, 2014, 15, 975-981.	3.4	19
228	Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond. Seminars in Oncology, 2014, 41, 235-251.	2.2	129
229	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2014, 12, 335-340.	1.9	9
230	Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma. European Urology, 2014, 65, 667-668.	1.9	3
231	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology, 2014, 65, 723-730.	1.9	69
232	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e127-e131.	1.9	25
233	Computed Tomography Characteristics of Unresectable Primary Renal Cell Carcinoma Treated With Neoadjuvant Sunitinib. Clinical Genitourinary Cancer, 2014, 12, 117-123.	1.9	2
234	Signal Integration and Gene Induction by a Functionally Distinct STAT3 Phosphoform. Molecular and Cellular Biology, 2014, 34, 1800-1811.	2.3	35

#	Article	IF	Citations
235	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European Urology, 2014, 65, 1086-1092.	1.9	71
236	Practice challenges affecting optimal care as identified by US medical oncologists who treat renal cell carcinomas. Journal of Community and Supportive Oncology, 2014, 12, 197-204.	0.1	1
237	Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer, 2013, 119, 313-324.	4.1	43
238	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	3.6	47
239	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncology, The, 2013, 14, 1233-1242.	10.7	215
240	Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1283-1291.	1.6	23
241	Metastatic nonâ€“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 2013, 119, 2999-3006.	4.1	189
242	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2013, 11, 311-315.	1.9	64
243	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology, The, 2013, 14, 141-148.	10.7	808
244	Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. Clinical Genitourinary Cancer, 2013, 11, 107-114.	1.9	42
245	Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective. Seminars in Oncology, 2013, 40, 419-420.	2.2	2
246	Metabolism of Kidney Cancer: From the Lab to Clinical Practice. European Urology, 2013, 63, 244-251.	1.9	61
247	Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 552-562.	10.7	640
248	A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Investigational New Drugs, 2013, 31, 1044-1050.	2.6	14
249	The Context of Blood Vessels and Response to VEGF-Targeted Therapy. Clinical Cancer Research, 2013, 19, 6647-6649.	7.0	3
250	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anti-Cancer Drugs, 2013, 24, 431-440.	1.4	13
251	Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. Journal of Clinical Pharmacology, 2013, 53, 491-504.	2.0	122
252	Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.. Journal of Clinical Oncology, 2013, 31, LBA349-LBA349.	1.6	8

#	Article	IF	Citations
253	Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2012, 2, 51.	2.8	18
254	Novel agents in renal carcinoma: a reality check. Therapeutic Advances in Medical Oncology, 2012, 4, 183-194.	3.2	53
255	The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery. Journal of Urology, 2012, 187, 1548-1554.	0.4	79
256	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncology, The, 2012, 13, 927-935.	10.7	112
257	State of the Science: An Update on Renal Cell Carcinoma. Molecular Cancer Research, 2012, 10, 859-880.	3.4	142
258	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer, 2012, 118, 1946-1954.	4.1	115
259	Castrationâ€resistant prostate cancer: Many treatments, many options, many challenges ahead. Cancer, 2012, 118, 2583-2593.	4.1	41
260	Cessation of vascular endothelial growth factorâ€“targeted therapy in patients with metastatic renal cell carcinoma. Cancer, 2012, 118, 3277-3282.	4.1	19
261	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney. Cancer, 2012, 118, 6152-6161.	4.1	97
262	Current Treatment Considerations in Metastatic Renal Cell Carcinoma. Current Treatment Options in Oncology, 2012, 13, 212-229.	3.0	30
263	Phase I/II trial of subcutaneous interleukinâ€2, granulocyteâ€macrophage colonyâ€stimulating factor and interferonâ€α in patients with metastatic renal cell carcinoma. BJU International, 2012, 109, 63-69.	2.5	12
264	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. European Urology, 2012, 61, 307-316.	1.9	52
265	p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. Seminars in Oncology, 2012, 39, 97-108.	2.2	51
266	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factorâ€targeted therapy. Cancer, 2012, 118, 365-370.	4.1	21
267	Determining the optimal dose and schedule of sunitinib. Cancer, 2012, 118, 1178-1180.	4.1	6
268	A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Investigational New Drugs, 2012, 30, 364-367.	2.6	14
269	Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.. Journal of Clinical Oncology, 2012, 30, 354-354.	1.6	12
270	Vascular Endothelial Growth Factorâ€“Targeted Therapies in Advanced Renal Cell Carcinoma. Hematology/Oncology Clinics of North America, 2011, 25, 813-833.	2.2	46

#	Article	IF	Citations
271	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. International Immunopharmacology, 2011, 11, 856-861.	3.8	257
272	Targeted therapy for patients with renal-cell carcinoma. Lancet Oncology, The, 2011, 12, 1085-1087.	10.7	8
273	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, The, 2011, 378, 1931-1939.	13.7	1,663
274	Clinical and immunomodulatory effects of bevacizumab and lowâ€dose interleukinâ€2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU International, 2011, 107, 562-570.	2.5	18
275	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. European Urology, 2011, 60, 684-690.	1.9	125
276	Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Investigational New Drugs, 2011, 29, 1441-1448.	2.6	13
277	Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining. Journal of Clinical Immunology, 2011, 31, 690-698.	3.8	13
278	Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. Journal of Cancer Survivorship, 2011, 5, 255-262.	2.9	4
279	Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes and Cancer, 2011, 50, 654-661.	2.8	33
280	Phase 1 doseâ€escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer, 2011, 117, 758-767.	4.1	143
281	The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer, 2011, 117, 1183-1189.	4.1	23
282	Progressionâ€free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer, 2011, 117, 2637-2642.	4.1	74
283	Sunitinib facilitates the activation and recruitment of therapeutic antiâ€tumor immunity in concert with specific vaccination. International Journal of Cancer, 2011, 129, 2158-2170.	5.1	127
284	Pazopanib for the treatment of renal cancer. Expert Opinion on Pharmacotherapy, 2011, 12, 1171-1189.	1.8	17
285	Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute, 2011, 103, 763-773.	6.3	526
286	Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. Clinical Cancer Research, 2011, 17, 3841-3849.	7.0	173
287	Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology, 2011, 13, 591-599.	1.2	295
288	Noncytotoxic Differentiation Treatment of Renal Cell Cancer. Cancer Research, 2011, 71, 1431-1441.	0.9	30

#	Article	IF	Citations
289	Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy. Clinical Advances in Hematology and Oncology, 2011, 9, 337-8.	0.3	3
290	Renal cell carcinoma: ten years of significant advances. Targeted Oncology, 2010, 5, 73-74.	3.6	4
291	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer, 2010, 116, 5383-5390.	4.1	63
292	Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer, 2010, 116, 5400-5406.	4.1	123
293	Association of percentage of tumour burden removed with debulking nephrectomy and progressionâ€free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factorâ€targeted therapy. BJU International, 2010, 106, 1266-1269.	2.5	65
294	Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy. American Journal of Roentgenology, 2010, 194, 1470-1478.	2.2	216
295	New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance. Clinical Cancer Research, 2010, 16, 1348-1354.	7.0	80
296	Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. Cancer Research, 2010, 70, 1063-1071.	0.9	394
297	Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma. Journal of Clinical Oncology, 2010, 28, e284-e285.	1.6	43
298	Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206. Journal of Clinical Oncology, 2010, 28, 2137-2143.	1.6	746
299	Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained. Cancer Research, 2010, 70, 3526-3536.	0.9	269
300	Editorial Comment. Urology, 2010, 75, 1114-1115.	1.0	0
301	Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. Urology, 2010, 76, 430-434.	1.0	75
302	Biomarkers: hypertension following anti-angiogenesis therapy. Clinical Advances in Hematology and Oncology, 2010, 8, 415-6.	0.3	12
303	Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. OncoTargets and Therapy, 2009, 2, 51.	2.0	30
304	Elevated Levels of Select Gangliosides in T Cells from Renal Cell Carcinoma Patients Is Associated with T Cell Dysfunction. Journal of Immunology, 2009, 183, 5050-5058.	0.8	48
305	GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells. Cancer Research, 2009, 69, 3095-3104.	0.9	57
306	Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. Clinical Cancer Research, 2009, 15, 2148-2157.	7.0	792

#	Article	IF	Citations
307	Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factorâ€“Targeted Therapy. Journal of Clinical Oncology, 2009, 27, 235-241.	1.6	214
308	A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 6277-6283.	7.0	84
309	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factorâ€“Targeted Agents: Results From a Large, Multicenter Study. Journal of Clinical Oncology, 2009, 27, 5794-5799.	1.6	1,751
310	Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF. Cancer Research, 2009, 69, 609-615.	0.9	238
311	Vascular endothelial growth factorâ€targeted therapy in metastatic renal cell carcinoma. Cancer, 2009, 115, 2306-2312.	4.1	84
312	Circulating tumor cells in metastatic castration-resistant prostate cancer. Current Oncology Reports, 2009, 11, 163-164.	4.0	0
313	Integration of surgery and systemic therapy in the management of metastatic renal cancer. Current Urology Reports, 2009, 10, 35-41.	2.2	9
314	The HLAâ€A2â€restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate, 2009, 69, 142-148.	2.3	10
315	Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient. Journal of Clinical Oncology, 2009, 27, 3225-3234.	1.6	105
316	Editorial Comment. Journal of Urology, 2009, 182, 2599-2600.	0.4	3
317	Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 4462-4468.	1.6	323
318	Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncology, The, 2009, 10, 992-1000.	10.7	496
319	Renal cell carcinoma. Lancet, The, 2009, 373, 1119-1132.	13.7	1,363
320	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity. American Journal of Surgical Pathology, 2009, 33, 72-80.	3.7	84
321	Renal Angiomyolipoma. American Journal of Surgical Pathology, 2009, 33, 289-297.	3.7	216
322	Sunitinibâ€induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer, 2008, 113, 1309-1314.	4.1	42
323	Axitinib for renal cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 741-748.	4.1	60
324	Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2008, 6, 79-85.	1.9	10

#	Article	IF	Citations
325	Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Review of Anticancer Therapy, 2008, 8, 895-905.	2.4	7
326	Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 543-549.	1.6	64
327	Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients. Clinical Cancer Research, 2008, 14, 6674-6682.	7.0	444
328	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 3743-3748.	1.6	381
329	Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. Journal of Clinical Oncology, 2008, 26, 5422-5428.	1.6	874
330	Lapatinib therapy for patients with advanced renal cell carcinoma. Nature Clinical Practice Oncology, 2008, 5, 626-627.	4.3	1
331	GM1 and Tumor Necrosis Factor-Î±, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis. Cancer Research, 2008, 68, 2014-2023.	0.9	38
332	Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin. Clinical Cancer Research, 2008, 14, 1286-1290.	7.0	156
333	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 127-131.	1.6	373
334	Is sorafenib plus interferon Î±2b safe and effective in patients with renal cell carcinoma?. Nature Reviews Urology, 2008, 5, 132-133.	1.4	7
335	Renal cell carcinoma. Current Opinion in Oncology, 2008, 20, 300-306.	2.4	120
336	Targeted therapy in renal cell carcinoma. Current Opinion in Urology, 2008, 18, 481-487.	1.8	14
337	PD2-3 Towards Optimal Management of Metastatic Renal Cell Carcinoma : an Update on the Role of Sunitinib as First-line Treatment. Japanese Journal of Urology, 2008, 99, 133.	0.1	0
338	Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?. Oncology, 2008, 22, 388-96; discussion 396, 402-3, 476 passim.	0.5	10
339	A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2007, 13, 1810-1815.	7.0	385
340	Sunitinib. Expert Opinion on Pharmacotherapy, 2007, 8, 2359-2369.	1.8	66
341	Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 741s-746s.	7.0	36
342	Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions. Clinical Cancer Research, 2007, 13, 1098-1106.	7.0	161

#	Article	IF	Citations
343	Response: Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute, 2007, 99, 976-977.	6.3	7
344	Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference: Fig. 1.. Clinical Cancer Research, 2007, 13, 667s-670s.	7.0	36
345	Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute, 2007, 99, 81-83.	6.3	370
346	Renal cell carcinoma. Current Opinion in Oncology, 2007, 19, 234-240.	2.4	13
347	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncology, The, 2007, 8, 975-984.	10.7	428
348	The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy. Journal of Urology, 2007, 177, 1978-1984.	0.4	81
349	Sorafenib in Advanced Renal Cancer. Drugs, 2007, 67, 484-485.	10.9	0
350	The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma. Scientific World Journal, The, 2007, 7, 800-807.	2.1	4
351	Temsirolimus. Nature Reviews Drug Discovery, 2007, 6, 599-600.	46.4	40
352	Immunotherapy for metastatic renal cell carcinoma. BJU International, 2007, 99, 1282-1288.	2.5	22
353	Recent Progress in the Management of Advanced Renal Cell Carcinoma. Ca-A Cancer Journal for Clinicians, 2007, 57, 112-125.	329.8	147
354	What Is Standard Initials Systemic Therapy in Metastatic Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2007, 5, 256-263.	1.9	2
355	The Prognostic Significance of Epidermal Growth Factor Receptor Expressionin Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation. Clinical Genitourinary Cancer, 2007, 5, 264-270.	1.9	26
356	A Phase I Trial of Docetaxel/Estramustine/Imatinib in Patients with Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer, 2007, 5, 323-328.	1.9	27
357	Prolonged Complete Responses and Near-Complete Responses to Sunitinib in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2007, 5, 446-451.	1.9	30
358	The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics. Targeted Oncology, 2007, 2, 225-234.	3.6	4
359	Sorafenib. Expert Opinion on Pharmacotherapy, 2006, 7, 453-461.	1.8	86
360	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 16-24.	1.6	1,590

#	Article	IF	Citations
361	Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. Biology of Blood and Marrow Transplantation, 2006, 12, 778-785.	2.0	40
362	Current status and future directions of molecular markers in renal cell carcinoma. Current Opinion in Urology, 2006, 16, 332-336.	1.8	16
363	Renal cell carcinoma. Current Opinion in Oncology, 2006, 18, 289-296.	2.4	32
364	Clinical trials in patients with biochemically relapsed prostate cancer. BJU International, 2006, 97, 905-910.	2.5	2
365	Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippelâ€Lindau gene status. BJU International, 2006, 98, 756-762.	2.5	104
366	A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU International, 2006, 98, 763-769.	2.5	54
367	VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices. Current Oncology Reports, 2006, 8, 85-89.	4.0	11
368	The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma. Seminars in Oncology, 2006, 33, 596-606.	2.2	34
369	Clinical Activity of Sorafenib and Sunitinib in Renal Cell Carcinoma Refractory to Previous Vascular Endothelial Growth Factorâ€“Targeted Therapy: Two Case Reports. Clinical Genitourinary Cancer, 2006, 5, 78-81.	1.9	16
370	Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2006, 5, 110-113.	1.9	16
371	Patients with Metastatic Renal Cell Carcinoma with Long-Term Disease-Free Survival After Treatment with Sunitinib and Resection of Residual Metastases. Clinical Genitourinary Cancer, 2006, 5, 232-234.	1.9	38
372	Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer, 2006, 106, 566-575.	4.1	56
373	Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer, 2006, 107, 67-74.	4.1	119
374	A phase II study of gemcitabine and capecitabine in metastatic renal cancer. Cancer, 2006, 107, 1273-1279.	4.1	68
375	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. JAMA - Journal of the American Medical Association, 2006, 295, 2516.	7.4	1,111
376	Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal-Cell Carcinoma. Journal of Endourology, 2006, 20, 504-508.	2.1	33
377	Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. Nature Clinical Practice Oncology, 2006, 3, 602-603.	4.3	9
378	Molecularly targeted therapy in renal cell carcinoma: where do we go from here?. Expert Review of Anticancer Therapy, 2006, 6, 1753-1760.	2.4	2

#	Article	IF	Citations
379	Renal cell carcinoma. Current Opinion in Oncology, 2005, 17, 261-267.	2.4	11
380	Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU International, 2005, 96, 286-290.	2.5	51
381	A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer, 2005, 103, 553-558.	4.1	19
382	VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma. Oncologist, 2005, 10, 191-197.	3.7	58
383	What are the prognostic factors for survival in patients with metastatic renal cell carcinoma?. Nature Clinical Practice Oncology, 2005, 2, 292-293.	4.3	1
384	Molecularly targeted therapy in renal cell carcinoma. Expert Review of Anticancer Therapy, 2005, 5, 1031-1040.	2.4	33
385	Antigen-Presenting Cells 8015 (ProvengeÂ®) in Patients with Androgen-Dependent, Biochemically Relapsed Prostate Cancer. Clinical Prostate Cancer, 2005, 4, 55-60.	2.1	55
386	SU11248 and AG013736: Current Data and Future Trials in Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2005, 4, 175-180.	1.9	16
387	Cancer and Leukemia Group B 90206. Clinical Cancer Research, 2004, 10, 2584-2586.	7.0	158
388	Recent clinical development of dendritic cell-based immunotherapy for prostate cancer. Expert Opinion on Biological Therapy, 2004, 4, 1729-1734.	3.1	6
389	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. Blood, 2004, 104, 810-810.	1.4	5
390	Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer. Journal of Clinical Oncology, 2003, 21, 99-105.	1.6	87
391	Allogeneic Stem-Cell Transplantation of Renal Cell Cancer After Nonmyeloablative Chemotherapy: Feasibility, Engraftment, and Clinical Results. Journal of Clinical Oncology, 2002, 20, 2017-2024.	1.6	169
392	Prostate cancer update. Current Opinion in Oncology, 2002, 14, 286-291.	2.4	23
393	A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer, 2002, 95, 1629-1636.	4.1	119
394	Hormone-Refractory prostate cancer. Current Treatment Options in Oncology, 2002, 3, 437-446.	3.0	21
395	Technology evaluation: APC-8015, Dendreon. Current Opinion in Molecular Therapeutics, 2002, 4, 76-9.	2.8	26
396	An update on prostate cancer. Current Opinion in Oncology, 2001, 13, 204-211.	2.4	12

#	Article	IF	Citations
397	Isolated, Primary Extranodal Hodgkin's Disease of the Spine: Case Report. Neurosurgery, 2001, 49, 453-457.	1.1	36
398	Immunotherapy for prostate cancer. Current Oncology Reports, 2001, 3, 418-423.	4.0	9
399	Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology, 2000, 18, 2419-2426.	1.6	154
400	Reply to S. Tan et al. Journal of Clinical Oncology, 0, , .	1.6	0